Filed pursuant to Rule 424(b)(3)
Registration No. 333-277016
PROSPECTUS SUPPLEMENT NO. 5
(to Prospectus dated April 3, 2024)
10,242,092 Ordinary Shares Represented by 10,242,092 American Depositary Shares Issuable Upon
Exercise of the Pre-Funded Warrants, Common Warrants, Series D Warrants and Series E Warrants
This prospectus supplement updates, amends and supplements the prospectus contained in our Post-Effective Amendment No. 1 to Form S-1, Post-Effective Amendment No. 2 to Form S-1 and Post-Effective Amendment No. 2 to Form S-1, effective as of April 3, 2024 (as supplemented or amended from time to time, the “Prospectus”) (Registration No. 333-277016). Capitalized terms used in this prospectus supplement and not otherwise defined herein have the meanings specified in the Prospectus.
This prospectus supplement is being filed to update, amend and supplement the information included in the Prospectus with the information contained in our Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on December 10, 2024, which is set forth below.
This prospectus supplement is not complete without the Prospectus. This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference.
Our ADSs are listed on the Nasdaq Capital Market under the symbol “QNRX”. On December 9, 2024, the closing price for our ADSs on the Nasdaq Capital Market was $0.78 per ADS.
Investing in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the risks and uncertainties under the heading “Risk Factors” beginning on page 5 of the Prospectus.
Neither the SEC nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense.
The date of this prospectus supplement is December 10, 2024.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 5, 2024
| QUOIN PHARMACEUTICALS LTD. |
| (Translation of registrant’s name into English) |
| State of Israel | 001-37846 | 92-2593104 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (I.R.S. Employer Identification No.) |
|
42127 Pleasant Forest Court Ashburn, VA |
20148-7349 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (703) 980-4182
| Not applicable |
| (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| American Depositary Shares, each representing one (1) Ordinary Share, no par value per share | QNRX | The Nasdaq Stock Market LLC | ||
| Ordinary Shares, no par value per share* | N/A |
| * | Not for trading, but only in connection with the registration of the American Depositary Shares pursuant to requirements of the Securities and Exchange Commission. |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 3.03. Material Modification to Rights of Security Holders.
Quoin Pharmaceuticals Ltd. (“we,” “us,” or the “Company”) held its 2024 Annual General Meeting of Shareholders (the “Annual Meeting”) on December 5, 2024. At the Annual Meeting, shareholders approved certain amendments (the “Amendments”) to the Company’s Amended and Restated Articles of Association, as amended (the “Articles”) including (i) an amendment to the special general meeting provision which conforms the ability of shareholders to request the Board to convene a special meeting to the provisions contained in the Israeli Companies Regulations (Relief for Companies with Securities Listed for Trading on a Foreign Stock Exchange), and (ii) an amendment to Section 22(b) of the Articles whereby the requisite quorum will be 33 1/3% (the quorum requirement for domestic filing companies under Nasdaq current corporate governance rules) unless the Company qualifies as a “foreign private issuer” under U.S. federal securities laws and the general meeting is convened pursuant to a resolution of the Board, in which case the requisite quorum will be 25% of the Company’s shares entitled to vote at a general meeting of the shareholders. A summary of the Amendments and the background of such Amendments is incorporated herein by reference from pages 23-24 of the Company’s definitive proxy statement on Schedule 14A for the Annual Meeting, as filed with the Securities and Exchange Commission on October 24, 2024.
The Amendments are attached as Exhibit 3.1 to this Current Report on Form 8-K and incorporated by reference herein.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Compensation Program for Dr. Michael Myers
At the Annual Meeting, the Company’s shareholders approved a compensation program for the Company’s Chief Executive Officer and Chairman of the Board, Dr. Michael Myers. The program sets forth the following compensation limitations applicable to Dr. Myers which the Compensation Committee and the Board can utilize in setting Dr. Myers’ compensation, beginning with the compensation to be paid in fiscal 2024, without the need to obtain further shareholder approval:
| (i) | an annual increase of base salary of up to 15% of Dr. Myers’ then effective base salary; | |
| (ii) | an annual cash bonus of up to 50% of Dr. Myers’ annual base salary during the fiscal year for which the annual cash bonus is paid (for example, Dr. Myers’ bonus to be paid in fiscal 2025 for fiscal 2024 services would be based upon a percentage, up to 50%, of Dr. Myers’ annual base salary in fiscal 2024); and | |
| (iii) | an annual equity grant in any form permitted under the Company’s equity incentive plan in effect from time to time with an annual value (determined in accordance with the Black-Scholes formula or another widely accepted and suitable formula for calculating the value of equity awards) of up to 500% of the maximum total fixed component (base salary and benefits) to which Dr. Myers is entitled in the grant year. |
(together the “CEO Compensation Program”).
In setting future compensation for Dr. Myers consistent with the terms of the CEO Compensation Program, the Compensation Committee and the Board will continue to annually review market competitive compensation as a reference, individual performance, the need to have appropriate incentives for our officers, and Dr. Myers’ experience and expected contributions. On December 9, 2024, the Compensation Committee and the Board took the following actions which were consistent with the Company’s Compensation Policy and within the limitations of the CEO Compensation Program: (i) approved and ratified Dr. Myers’ 2024 annual base salary at $662,475 (retroactive to January 1, 2024), (ii) approved and ratified a discretionary cash bonus for Dr. Myers for fiscal 2023 services of $301,125; and (iii) granted Dr. Myers an option to purchase 536,603 ADSs under Quoin’s Amended and Restated Equity Incentive Plan (the “Plan”),with an exercise price equal to $0.78 per ADS, the fair market value on the date of grant.
Compensation Program for Denise Carter
Also at the Annual Meeting, the Company’s shareholders approved a compensation program for the Company’s Chief Operating Officer and a Member of the Board, Denise Carter. The program sets forth the following compensation limitations applicable to Ms. Carter which the Compensation Committee and the Board can utilize in setting Ms. Carter’s compensation, beginning with the compensation to be paid in fiscal 2024, without the need to obtain further shareholder approval:
| (i) | an annual increase of base salary of up to 15% of Ms. Carter’s then effective base salary; | |
| (ii) | an annual cash bonus of up to 50% of Ms. Carter’s annual base salary during the fiscal year for which the annual cash bonus is paid (for example, Ms. Carter’s bonus to be paid in fiscal 2025 for fiscal 2024 services would be based upon a percentage, up to 50%, of Ms. Carter’s annual base salary in fiscal 2024); and | |
| (iii) | an annual equity grant in any form permitted under the Company’s equity incentive plan in effect from time to time with an annual value (determined in accordance with the Black-Scholes formula or another widely accepted and suitable formula for calculating the value of equity awards) of up to 500% of the maximum total fixed component (base salary and benefits) to which Ms. Carter is entitled in the grant year. |
(together the “COO Compensation Program”).
In setting future compensation for Ms. Carter consistent with the terms of the CEO Compensation Program, the Compensation Committee and the Board will continue to annually review market competitive compensation as a reference, individual performance, the need to have appropriate incentives for our officers, and Ms. Carter’s experience and expected contributions. On December 9, 2024, the Compensation Committee and the Board took the following actions which were consistent with the Company’s Compensation Policy and within the limitations of the COO Compensation Program: (i) approved and ratified Ms. Carter’s 2024 annual base salary at $529,980 (retroactive to January 1, 2024), (ii) approved and ratified a discretionary cash bonus for Ms. Carter for fiscal 2023 services of $240,900; and (iii) granted Ms. Carter an option to purchase 536,609 ADSs under Quoin’s Plan, with an exercise price equal to $0.78 per ADS, the fair market value on the date of grant.
Compensation Matters Related to Gordon Dunn
On December 9, 2024, the Compensation Committee and the Board took the following actions which were consistent with the Company’s Compensation Policy: (i) approved and ratified the setting of the 2024 annual base salary for Gordon Dunn, our Chief Financial Officer, at $433,620 (retroactive to January 1, 2024), (ii) approved and ratified a discretionary cash bonus for Mr. Dunn for fiscal 2023 services of $197,100; and (iii) granted Mr. Dunn an option to purchase 338,994 ADSs under Quoin’s Plan, with an exercise price equal to $0.78 per ADS, the fair market value on the date of grant.
Item 5.07. Submission of Matters to a Vote of Security Holders.
During the Annual Meeting, shareholders were asked to consider and vote upon seven proposals. These matters are described in detail in the Company’s definitive proxy statement on Schedule 14A for the Annual Meeting, which was filed on October 24, 2024 with the Securities and Exchange Commission.
On the record date of October 21, 2024, there were 5,049,720 ordinary shares issued and outstanding and entitled to vote at the Annual Meeting, represented by 5,049,720 ADSs (assuming all ordinary shares are represented by ADSs). For each proposal, the results of the shareholder voting were as follows:
1. The shareholders elected the following directors to serve on Quoin’s Board of Directors until Quoin’s 2025 annual meeting of shareholders and until such director’s successor is duly elected and qualified, or until such director’s earlier resignation or retirement, based upon the following votes:
| Directors | For | Against | Abstain | Broker Non-Votes | ||||||||||||
| Dr. Michael Myers | 335,814 | 58,696 | 37,833 | 1,274,513 | ||||||||||||
| Denise Carter | 334,551 | 59,959 | 37,833 | 1,274,513 | ||||||||||||
| Joseph Cooper | 327,567 | 66,143 | 38,633 | 1,274,513 | ||||||||||||
| James Culverwell | 335,593 | 58,917 | 37,833 | 1,274,513 | ||||||||||||
| Dr. Dennis H. Langer | 334,852 | 59,658 | 37,833 | 1,274,513 | ||||||||||||
| Natalie Leong | 327,430 | 67,080 | 37,833 | 1,274,513 | ||||||||||||
| Michael Sember | 335,521 | 58,989 | 37,833 | 1,274,513 | ||||||||||||
2. The shareholders approved certain amendments to the Company’s Amended and Restated Articles of Association, as amended, based upon the following votes:
| For | Against | Abstain | Broker Non-Votes | ||||||
| 338,751 | 53,072 | 40,520 | 1,274,513 |
3. The shareholders approved the terms of a compensation program for Dr. Michael Myers, the Company’s Chief Executive Officer and Chairman, based upon the following votes:
| For | Against | Abstain | Broker Non-Votes | ||||||
| 264,179 | 90,283 | 30,629 | 1,274,513 |
4. The shareholders approved the terms of a compensation program for Denise Carter, the Company’s Chief Operating Officer and a member of the Board, based upon the following votes:
| For | Against | Abstain | Broker Non-Votes | ||||||
| 264,357 | 88,577 | 32,317 | 1,274,513 |
5. The shareholders approved the changes to the Company’s non-employee directors’ compensation program, based upon the following votes:
| For | Against | Abstain | Broker Non-Votes | ||||||
| 295,012 | 106,161 | 31,170 | 1,274,513 |
6. The shareholders approved the appointment of Marcum LLP to serve as the Company’s auditor and independent registered public accounting firm until the Company’s next annual general meeting of shareholders, based upon the following votes:
| For | Against | Abstain | Broker Non-Votes | ||||||
| 1,555,827 | 85,376 | 65,653 | - |
7. The shareholders approved Dr. Michael Myer’s service as both the Company’s Chief Executive Officer and the Chairman of the Company’s Board for a period of three years, based upon the following votes.
| For | Against | Abstain | Broker Non-Votes | ||||||
| 265,990 | 80,417 | 38,684 | 1,274,513 |
Item 8.01. Other Events.
At the Annual Meeting, shareholders approved certain amendments to the Company’s non-employee directors’ compensation program (the “NED Program”), which was previously approved by the Company’s shareholders at the Annual General Meeting held on April 12, 2022 (the “2022 AGM”). The amendments to the NED Program approved at the Annual Meeting provide that, (i) the annual base retainer was increased to $82,500; and (ii) the annual option grant was changed from a fixed value to a varying amount of no less than $20,000 and no more than $60,000, with such value being determined annually at the discretion of the Compensation Committee and the Board. The remaining terms set forth in the NED Program, as approved at the 2022 AGM, remain unchanged. On December 9, 2029, the Compensation Committee and the Board granted each non-employee director an option to purchase 57,014 ADSs under Quoin’s Plan, with an exercise price equal to $0.78 per ADS, the fair market value on the date of grant.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. |
Description | |
| 3.1 | Amendments to Amended and Restated Articles of Association of Quoin Pharmaceuticals Ltd., adopted on December 5, 2024. | |
| 104 | Cover Page Interactive Data file (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| Date: December 10, 2024 | QUOIN PHARMACEUTICALS LTD. | |
| By: | /s/ Gordon Dunn | |
| Name: | Gordon Dunn | |
| Title: | Chief Financial Officer | |
Exhibit 3.1
Form of Amendment to the Articles
The Companies Law, 5759-1999
Quoin Pharmaceuticals Ltd., Company No. 52-003648-4 (the “Company”)
Amendment to the Company's Articles of Association (the “Articles”)
adopted at the Company's Annual General Meeting
Section 19 of the Articles of Association is amended as follows (additions in underline and deletions in strikethrough):
19. Special General Meetings
(a) At any time, the Board of Directors may convene a General Meeting of the Company’s shareholders other than the Annual Meeting (a “Special General Meeting”) by means of a Board resolution.
(b) The Board of Directors shall convene a Special General Meeting upon the demand of each of the following:
| (1) | Two Directors, or a quarter of the Directors then serving; |
| One or more shareholders of the Company holding at least the required percentage under the Companies Law. |
Section 22(b) of our Articles of Association is amended as follows (additions in underline and deletions in strikethrough):
22 Quorum
| (a) | Proceedings in the General Meeting shall not commence until a quorum is present at the start of the proceedings. |
| (b) |